Mereo BioPharma Faces Class Action Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Should l Buy MREO?
Source: Globenewswire
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Mereo BioPharma Group plc for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between June 5, 2023, and December 26, 2025.
- False Statements Exposed: The complaint alleges that Mereo concealed negative facts regarding its Phase 3 ORBIT and COSMIC programs, rendering the company's public statements throughout the class period false and materially misleading.
- Investor Losses: As the market learned the truth about Mereo's failure to meet primary endpoints, investors suffered damages, indicating a significant impact on investor confidence and the company's reputation.
- Legal Consultation Opportunity: The Schall Law Firm encourages affected shareholders to contact them before April 6, 2026, to participate in the class action and seek compensation, highlighting the importance of investor protection.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MREO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MREO
Wall Street analysts forecast MREO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MREO is 2.08 USD with a low forecast of 0.50 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
6 Buy
2 Hold
0 Sell
Strong Buy
Current: 0.388
Low
0.50
Averages
2.08
High
5.00
Current: 0.388
Low
0.50
Averages
2.08
High
5.00
About MREO
Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development, which include Etigilimab, an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity and Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late-line ovarian cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Mereo BioPharma Faces Class Action Lawsuit
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Mereo BioPharma Group plc for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between June 5, 2023, and December 26, 2025.
- False Statements Exposed: The complaint alleges that Mereo concealed negative facts regarding its Phase 3 ORBIT and COSMIC programs, rendering the company's public statements throughout the class period false and materially misleading.
- Investor Losses: As the market learned the truth about Mereo's failure to meet primary endpoints, investors suffered damages, indicating a significant impact on investor confidence and the company's reputation.
- Legal Consultation Opportunity: The Schall Law Firm encourages affected shareholders to contact them before April 6, 2026, to participate in the class action and seek compensation, highlighting the importance of investor protection.
See More
Class Action Reminder for Mereo BioPharma Shareholders
- Lawsuit Background: Robbins LLP reminds all investors who purchased Mereo BioPharma Group plc (NASDAQ: MREO) American Depository Shares between June 5, 2023, and December 26, 2025, that a class action has been filed, alleging the company misled investors regarding the outcomes of its drug studies.
- Study Failures: The complaint states that Mereo failed to meet the primary endpoints in its Phase 3 ORBIT and COSMIC studies for Osteogenesis Imperfecta, which did not demonstrate a reduction in annualized clinical fracture rates compared to placebo or bisphosphonate controls, resulting in significant investor losses.
- Stock Price Plunge: Following the announcement on December 29, 2025, that the studies did not achieve their goals, Mereo's ADS price plummeted from $2.31 per share on December 26, 2025, to $0.29 per share, a decline of over 87.7%, reflecting extreme market disappointment in the company's prospects.
- Shareholder Action: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by April 6, 2026, highlighting deficiencies in corporate governance and the potential impact on investors, underscoring the company's lack of transparency and accountability.
See More
Class Action Lawsuit Filed Against Mereo BioPharma Group
- Lawsuit Background: Berger Montague PC has announced a class action lawsuit against Mereo BioPharma Group plc on behalf of investors who purchased American Depositary Shares between June 5, 2023, and December 26, 2025, alleging the company misled investors regarding the ORBIT and COSMIC studies.
- Investor Losses: Following the lawsuit disclosure, Mereo's ADS price plummeted from $2.31 on December 26, 2025, to $0.29 on December 29, 2025, erasing over 87.7% of its value in a single day, severely impacting investor confidence and the company's market capitalization.
- Investor Rights: Investors must apply by April 6, 2026, to be appointed as lead plaintiff representatives in the class action, highlighting the importance of legal proceedings in protecting investor interests.
- Company Overview: Mereo, headquartered in London, specializes in treatments for rare diseases, but the lawsuit reveals a lack of transparency in its clinical trials, which could affect future funding and market reputation.
See More
Class Action Lawsuit Announced for Mereo BioPharma
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit against Mereo BioPharma Group plc, covering purchasers of American Depositary Shares from June 5, 2023, to December 26, 2025, aiming to seek compensation for affected investors, indicating significant legal risks for the company.
- Lawsuit Background: The lawsuit alleges that defendants made false or misleading statements regarding the Phase 3 ORBIT and COSMIC programs, which failed to meet primary endpoints for reducing clinical fracture rates, resulting in investor losses when the truth emerged, highlighting major failures in the company's R&D efforts.
- Investor Rights Protection: Investors joining the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, thereby reducing legal risks for investors and encouraging more affected parties to participate.
- Law Firm's Strengths: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling similar cases.
See More
Class Action Lawsuit Announced for Mereo BioPharma
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit against Mereo BioPharma Group plc for investors who purchased American Depositary Shares between June 5, 2023, and December 26, 2025, indicating significant legal risks that could undermine shareholder confidence.
- Compensation Mechanism: Investors participating in the lawsuit may receive compensation without any out-of-pocket costs, suggesting that the lawsuit could attract a large number of affected investors, thereby increasing the company's potential financial liabilities.
- Lawsuit Background: The lawsuit alleges that Mereo BioPharma concealed the true status of its Phase 3 ORBIT and COSMIC programs, which failed to meet primary clinical trial endpoints, leading to investor losses and highlighting the company's lack of transparency in R&D.
- Law Firm's Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having secured hundreds of millions in settlements, which may further impact Mereo BioPharma's reputation as it navigates this legal challenge.
See More
Class Action Filed Against Mereo BioPharma Group plc
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Mereo BioPharma Group plc, seeking damages for investors who acquired Mereo securities between June 5, 2023, and December 26, 2025, indicating significant legal risks for the company.
- Allegations of False Statements: The complaint alleges that Mereo provided overly positive statements to investors while concealing material adverse facts regarding the Phase 3 ORBIT and COSMIC programs, leading to investor misconceptions about the company's prospects.
- Clinical Trial Failures: The lawsuit highlights that Mereo's two critical clinical trials failed to meet their primary endpoints, failing to effectively reduce the annualized clinical fracture rate compared to placebo or bisphosphonate control groups, which could negatively impact the company's future market performance.
- Investor Action Deadline: Affected investors have until April 6, 2026, to request to be appointed as lead plaintiff, demonstrating the urgency and proactive nature of investors in the legal proceedings.
See More
Mereo BioPharma Faces Class Action Lawsuit
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Mereo BioPharma Group plc for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between June 5, 2023, and December 26, 2025.
- False Statements Exposed: The complaint alleges that Mereo concealed negative facts regarding its Phase 3 ORBIT and COSMIC programs, rendering the company's public statements throughout the class period false and materially misleading.
- Investor Losses: As the market learned the truth about Mereo's failure to meet primary endpoints, investors suffered damages, indicating a significant impact on investor confidence and the company's reputation.
- Legal Consultation Opportunity: The Schall Law Firm encourages affected shareholders to contact them before April 6, 2026, to participate in the class action and seek compensation, highlighting the importance of investor protection.
See More
Class Action Reminder for Mereo BioPharma Shareholders
- Lawsuit Background: Robbins LLP reminds all investors who purchased Mereo BioPharma Group plc (NASDAQ: MREO) American Depository Shares between June 5, 2023, and December 26, 2025, that a class action has been filed, alleging the company misled investors regarding the outcomes of its drug studies.
- Study Failures: The complaint states that Mereo failed to meet the primary endpoints in its Phase 3 ORBIT and COSMIC studies for Osteogenesis Imperfecta, which did not demonstrate a reduction in annualized clinical fracture rates compared to placebo or bisphosphonate controls, resulting in significant investor losses.
- Stock Price Plunge: Following the announcement on December 29, 2025, that the studies did not achieve their goals, Mereo's ADS price plummeted from $2.31 per share on December 26, 2025, to $0.29 per share, a decline of over 87.7%, reflecting extreme market disappointment in the company's prospects.
- Shareholder Action: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by April 6, 2026, highlighting deficiencies in corporate governance and the potential impact on investors, underscoring the company's lack of transparency and accountability.
See More
Class Action Lawsuit Filed Against Mereo BioPharma Group
- Lawsuit Background: Berger Montague PC has announced a class action lawsuit against Mereo BioPharma Group plc on behalf of investors who purchased American Depositary Shares between June 5, 2023, and December 26, 2025, alleging the company misled investors regarding the ORBIT and COSMIC studies.
- Investor Losses: Following the lawsuit disclosure, Mereo's ADS price plummeted from $2.31 on December 26, 2025, to $0.29 on December 29, 2025, erasing over 87.7% of its value in a single day, severely impacting investor confidence and the company's market capitalization.
- Investor Rights: Investors must apply by April 6, 2026, to be appointed as lead plaintiff representatives in the class action, highlighting the importance of legal proceedings in protecting investor interests.
- Company Overview: Mereo, headquartered in London, specializes in treatments for rare diseases, but the lawsuit reveals a lack of transparency in its clinical trials, which could affect future funding and market reputation.
See More
Class Action Lawsuit Announced for Mereo BioPharma
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit against Mereo BioPharma Group plc, covering purchasers of American Depositary Shares from June 5, 2023, to December 26, 2025, aiming to seek compensation for affected investors, indicating significant legal risks for the company.
- Lawsuit Background: The lawsuit alleges that defendants made false or misleading statements regarding the Phase 3 ORBIT and COSMIC programs, which failed to meet primary endpoints for reducing clinical fracture rates, resulting in investor losses when the truth emerged, highlighting major failures in the company's R&D efforts.
- Investor Rights Protection: Investors joining the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, thereby reducing legal risks for investors and encouraging more affected parties to participate.
- Law Firm's Strengths: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling similar cases.
See More
Class Action Lawsuit Announced for Mereo BioPharma
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit against Mereo BioPharma Group plc for investors who purchased American Depositary Shares between June 5, 2023, and December 26, 2025, indicating significant legal risks that could undermine shareholder confidence.
- Compensation Mechanism: Investors participating in the lawsuit may receive compensation without any out-of-pocket costs, suggesting that the lawsuit could attract a large number of affected investors, thereby increasing the company's potential financial liabilities.
- Lawsuit Background: The lawsuit alleges that Mereo BioPharma concealed the true status of its Phase 3 ORBIT and COSMIC programs, which failed to meet primary clinical trial endpoints, leading to investor losses and highlighting the company's lack of transparency in R&D.
- Law Firm's Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having secured hundreds of millions in settlements, which may further impact Mereo BioPharma's reputation as it navigates this legal challenge.
See More
Class Action Filed Against Mereo BioPharma Group plc
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Mereo BioPharma Group plc, seeking damages for investors who acquired Mereo securities between June 5, 2023, and December 26, 2025, indicating significant legal risks for the company.
- Allegations of False Statements: The complaint alleges that Mereo provided overly positive statements to investors while concealing material adverse facts regarding the Phase 3 ORBIT and COSMIC programs, leading to investor misconceptions about the company's prospects.
- Clinical Trial Failures: The lawsuit highlights that Mereo's two critical clinical trials failed to meet their primary endpoints, failing to effectively reduce the annualized clinical fracture rate compared to placebo or bisphosphonate control groups, which could negatively impact the company's future market performance.
- Investor Action Deadline: Affected investors have until April 6, 2026, to request to be appointed as lead plaintiff, demonstrating the urgency and proactive nature of investors in the legal proceedings.
See More
